



MARKET RELEASE

24 February 2016

Optiscan Imaging Limited

SUSPENSION FROM OFFICIAL QUOTATION

The securities of Optiscan Imaging Limited (the “Company”) will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

Security Code: OIL

Kobe Li

SENIOR ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



24 February 2016

REQUEST FOR SUSPENSION

Optiscan Imaging Limited (ASX:OIL) requested a trading halt with immediate effect, after close of market on Friday 19 February 2016, pending an announcement to the market concerning fund raising.

OIL had entered into a non-binding term sheet to arrange R&D Finance through the issue of secured convertible notes which was subject to, inter alia, due diligence being completed by Friday 26 February 2016. The Company also entered into a mandate to arrange a placement. OIL has now been advised that both mandates have been terminated.

As the anticipated fund raising (debt & equity) is incomplete, the Company requests a suspension of trading in its shares whilst further options are considered to deal with its immediate solvency.

Further announcements are expected to be made no later than Monday 29 February 2016.

About Optiscan

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Further information:

Peter Delaney, Director of Technology
Tel (613) 9538 3391
PeterD@optiscan.com

Bruce Andrew, CFO
Tel (613) 9538 3398
brucea@optiscan.com